Page last updated: 2024-10-24
calmidazolium and African Lymphoma
calmidazolium has been researched along with African Lymphoma in 1 studies
calmidazolium: powerful inhibitor of or red blood cell Ca++-ATPase & Ca++ transport into inside-out red blood cell vesicles; RN refers to chloride; structure in first source; an antagonist of calmodulin
calmidazolium : An imidazolium ion that is imidazolium cation substituted by a bis(4-chlorophenyl)methyl group at position 1 and a 2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl group at position 3. It acts as an antagonist of calmodulin, a calcium binding messenger protein.
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Duraj, J | 1 |
Kovacikova, M | 1 |
Sedlak, J | 1 |
Koppel, J | 1 |
Sobel, A | 1 |
Chorvath, B | 1 |
Other Studies
1 other study available for calmidazolium and African Lymphoma
Article | Year |
---|---|
The protein kinase C inhibitor H7 blocks phosphorylation of stathmin during TPA-induced growth inhibition of human pre-B leukemia REH6 cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Burkitt Lymphoma; Calmodulin; Cell Cycle; Cell Divisi | 1995 |